Stéphane Bancel

Director & Chief Executive Officer at Moderna, Inc.

Stéphane Bancel

Stéphane Bancel

Director & Chief Executive Officer at Moderna, Inc.

Overview
Career Highlights

Eli Lilly & Company
Moderna, Inc.
Modernatx, Inc.

RelSci Relationships

4953

Number of Boards

11

Birthday

1973

Age

48

Number of Awards

4

Relationships
RelSci Relationships are individuals Stéphane Bancel likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Moderna, Inc.

Relationship likelihood: Strong

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Managing Partner at Flagship Pioneering

Relationship likelihood: Strong

Managing Partner at Flagship Pioneering

Relationship likelihood: Strong

President at Moderna, Inc.

Relationship likelihood: Strong

Founder at Fate Therapeutics, Inc.

Relationship likelihood: Strong

Chief Operating Officer & Chief of Staff at Oncorus, Inc.

Relationship likelihood: Strong

President at Brigham & Women's Physicians Organization, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Qiagen N.V.

Relationship likelihood: Strong

Member-Sports Board at The University of Nottingham

Relationship likelihood: Strong

Paths to Stéphane Bancel
Potential Connections via
Relationship Science
You
Stéphane Bancel
Director & Chief Executive Officer at Moderna, Inc.
Family Members
Spouse
Education
M.B.A.
Class of 2000

Harvard Business School (HBS) is the graduate business school of Harvard University in Boston, Massachusetts, United States. The school offers a large full-time MBA program, doctoral programs, and many executive education programs. It owns Harvard Business School Publishing, which publishes business books, leadership articles, online management tools for corporate learning, case studies, and the monthly Harvard Business Review.

Master of Engineering
Class of 1995

Since its foundation in 1829, the École Centrale Paris has followed the same calling: training engineers capable of meeting the greatest challenges of their era. The challenge is to allow the 9 billion people who will live on our planet in 2050 to have access to water, food, energy, health, education, information, etc. To appreciate and meet the great challenges of the 21st century, the world needs ever more engineers – “three- dimensional” engineers: high level scientific and technical generalists, experts in initiating and piloting innovative projects and with a strong international culture. It is these new scientific leaders, entrepreneurs and innovators, that Centrale Paris seeks to train and to prepare for the companies, governments and institutions of today and tomorrow. These men and women will know how to respond to the issues of their age using the science and technology.

Master of Science in Chemical Engineering

The University of Minnesota, Twin Cities (Minnesota, U of M, or The U) is a public research university located in Minneapolis and St. Paul, Minnesota, United States, with the Minneapolis and St. Paul campuses being approximately 5 miles (8.0 km) apart. It is the oldest and largest campus within the University of Minnesota system and has the sixth-largest main campus student body in the United States, with 51,853 students in 2012–2013. The university is broadly organized into 19 colleges and schools, and it has sister campuses in Crookston, Duluth, Morris, and Rochester.

Unknown

CentraleSupélec operates as a higher education and research institution. The firm is a public institution under ministerial charter, devoted to the sciences and engineering. The company was founded on January 1, 2015 and is headquartered in Paris, France.

Memberships
Member
Current

CEO Action For Diversity & Inclusion is the CEO-driven business commitment to advance diversity and inclusion within the workplace. The company is headquartered in Chicago, IL.

Career History
Special Partner
2013 - Current

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Director & Chief Executive Officer
2011 - Current

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Chief Executive Officer
2011 - Current

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Boards & Committees
Director
2008 - 2009

Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$25K +
2019

The Epiphany School, Inc. provides education services. The company is headquartered in Dorchester, MA.

$5,000 - $10K
2019

Posse Foundation is a nonprofit company headquartered in New York, NY. The firm operates as nonprofit organization that provides recruitment services for students. It was founded by Deborah Bial.

$25K +
2018

The Epiphany School, Inc. provides education services. The company is headquartered in Dorchester, MA.

Transactions
Details Hidden

Moderna, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
2017
Ernst & Young - Entrepreneur of the Year New England
Rank #1
2011
Thomson Reuters Pan European EXTEL Study - CEO in the Biotechnology Sector
2009
World Economic Forum - Young Global Leaders
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stéphane Bancel. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stéphane Bancel's profile does not indicate a business or promotional relationship of any kind between RelSci and Stéphane Bancel.